Abstract: A compression device can include an adjustable belt, an inflation bladder, and a control module. The adjustable belt can be sized to fit circumferentially around a subject's abdomen. The inflatable bladder and the control module can be secured to the belt. The control module can include a housing that encloses at least one of a pump, a pressure relief valve, and a controller. The pump and the pressure relief valve can be in fluid communication with the bladder. The pump can be configured to inflate the bladder to a pre-determined pressure and apply a compressive pressure to the subject's abdomen. The pressure relief valve can be configured to decrease the pressure within the bladder. The controller can be configured to automatically adjust the compressive pressure in response to a change in the subject's posture. The controller can be in electrical communication with the pump and the pressure relief valve.

Abstract: A massage apparatus is provided with a movable base frame at the bottom, a massage mechanism and a pressure sensing and adapting drive mechanism. The massage mechanism and the pressure sensing and adapting drive mechanism are provided on the movable base frame. The massage mechanism has a left and a right clamp plate, a linking post, a malaxation part and a pummelling part. The left and right clamp plates are fixedly provided on the movable base frame, and the malaxation part and the pummelling part are provided between the left and right clamp plates. The massage apparatus automatically senses the massage pressure and automatically adjusts the massage pressure in real-time within a provided pressure range according to the different body types of users. The massage apparatus automatically adapts to changes in the height and the curvature of the back of the human body in the course of massaging.

Abstract: A rejuvenation and massage device is provided for treating mucosa tissue, such as vaginal tissue, affected by Vaginal Relaxation Syndrome (VRS) or other conditions, through vibration, thermal loading, and light emittance for a duration of time. In one embodiment, the device is an insertable device that includes Low-Level Laser Light (LLLT) therapy to treat the vaginal tissue. The light emittance by one or more light emitters is in a range sufficient to provide therapeutic effects through light radiation. To enhance the therapeutic effects of light radiation provided by the device, the device is configured to provide increased energy density into target tissue of vaginal muscles though a light configuration component (e.g., a focusing component, such as a concave lens assembly, a convex assembly, a pre-lensed light emitter or other focusing optical mechanism) associated with the light emitter that concentrates the light emitted from the light emitter.

Abstract: Systems and methods for determining depth of compressions of a chest of a patient receiving chest compressions. A field detector is used having at least two coils at a fixed distance from each other.

Abstract: The present invention relates generally to a support structure for fixating a patient to a treatment unit, and especially to a support structure for fixating the patient to a cardiopulmonary resuscitation unit. An embodiment of the support structure includes a back plate for positioning behind the patient's back posterior to the patient's heart and a front part for positioning around the patient's chest anterior to the patient's heart. Further, the front part can include two legs, each leg having a first end pivotably connected to at least one hinge and a second end removably attachable to the back plate. The front part can further be devised for including a compression/decompression unit arranged to automatically compress or decompress the patient's chest when the front part is attached to the back plate.

Abstract: Disclosed herein are systems, methods, and devices for implementing a rotating control panel. Systems include an enclosed space of a sauna comprising a plurality of walls, an opening in at least one of the plurality of walls, and a control panel configured to be coupled with at least one heating element. The control panel includes an axis of rotation and a plurality of controls. Systems also include a rotating mount coupled with the control panel at the axis of rotation to enable the control panel to rotate at least 180 degrees within the opening of the a wall of the enclosed space of the sauna without disconnecting the at least one electrical connector. Systems include an insulating seal coupled with the control panel and configured to contact the opening when the control panel is coplanar with the wall while allowing the control panel to rotate freely within the opening.

Abstract: A kit for discharging electrons from a mammal such as human comprise at least two electrically conductive acupuncture needles. The needles are adapted for creating an electrical connection with subcutaneous tissue of the mammal. There is an electrically conductive pad with electrically conductive pad wires, one for each needle for connection to the respective needle to the pad. Electrically conductive grounding wire is provided for electrically grounding the pad. Helical wires for placement around the acupuncture needles can be used to enhance electrically conductivity. The kit is designed, when assembled and used to treat a mammal, for withdrawing excess electrons from the mammals for improved health.

Abstract: A package includes a container made from a paperboard, cardboard or other foldable sheet material, and houses at least one blister pack. The blister pack is secured within an internal space of the container by means of a frangible connection, breakage of the frangible connection allowing complete removal of the blister pack from the container.

Abstract: Medicinal container bags are presented. Bags can include openers capable of sealing an opening of the bag. Disclosed bags further comprise electronic assemblies configured to detect opening or closing events as the openers move along the rims of the bag opening. The assemblies can compile usage data based on opener movement, and then provide the data to remote monitoring systems.

Abstract: A bottle stand includes a bottle holder and at least one posably flexible leg having a proximal end attached to the bottle holder and a distal end resting on a surface, the leg comprising a first member and a second member telescopically coupled to the first member.

Abstract: Cosmetic compositions and methods for changing the color of keratinic fibers are provided herein. In an embodiment, a cosmetic composition for lightening the color of keratinic fibers includes at least two separately packaged formulations (A) and (B), which are mixed immediately prior to application to give an application mixture. The formulation (A) includes at least one dye chosen from the group of oxidation dye precursors, direct dyes, or a combination thereof. The composition (B) is a flowable composition including water and at least one oxidizing agent. Formulation (A) has been packaged in a water-soluble film including, based on its total weight, at least about 60% by weight of a polymer mixture having a multimodal molecular weight distribution.

Abstract: In one aspect, the present invention is directed to formulations comprising at least one pressure generating vehicle along with at least one skincare active agent in a container such that the pressure generating vehicle would eject the formulation as foam, whipped cream or a similar form upon application of external pressure on the container.

Abstract: An autophage activating resveratrol topical composition includes a ceramide or a pseudoceramide, a fatty acid, a phytosterol, and a resveratrol. The ceramide or pseudoceramide, the fatty acid, the phytosterol, and the resveratrol form a multi-layered encapsulation system. A method of inducing autophagy in skin includes applying the autophage activating resveratrol topical composition to a skin, and inducing autophagy in the skin to improve skin barrier function and skin self-purification function.

Abstract: A composition is provided, wherein the composition comprises a water-swellable, water insoluble polymer, a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding to the hydrophilic polymer, and a whitening agent, preferably a peroxide. The composition finds utility as a tooth whitening composition and is applied to the teeth in need of whitening, and then removed when the degree of whitening has been achieved. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.

Abstract: The present invention relates to a composition for dyeing keratin fibers, in particular keratin fibers such as the hair, comprising: a) at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof and/or solvates thereof such as hydrates; b) at least one coupler; c) at least one polymer chosen from cationic polymers and amphoteric polymers, and mixtures thereof; d) at least one fatty substance; the total amount of fatty substances being at least 10%, e) optionally at least one basifying agent; and f) optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibers such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention.

Abstract: An oral care composition comprising zinc phosphate, stannous fluoride, arginine or lysine and an organic acid buffer system, as well as methods of using the same.

Abstract: Agents for the reductive decolorization of dyed keratin fibers contain, in a cosmetic carrier, (a) at least one compound of formula (I), A[(CR1R2)SO2M]p,q (I), in which A represents N(R3)3-q or O(R4)2-p, R1, R2, R4 represent a hydrogen atom or a C1-C6 alkyl group, R3 represents residues selected from the group of a hydrogen atom, a C1-C20 alkyl group, a C3-C8 cycloalkyl group optionally substituted with one to three C1-C4 alkyl residues, M represents residues selected from a hydrogen atom or an equivalent of an alkali metal ion, alkaline-earth metal ion, or metal ion, p represents 1 or 2, q represents 1, 2, or 3, wherein at least one of R1, R2, R4 represents a C1-C6 alkyl group if A represents O(R42-p), and R3 does not represent a hydrogen atom if q equals 1, and (b) optionally at least one compound of formula (II), A[(CR1R2)SO3M]p,q (II).

Abstract: An aqueous cleansing composition comprising a cationic surfactant, a nonionic surfactant, and a thickener comprising an alkoxylated methyl glucose ether, wherein a weight ratio of cationic surfactant to nonionic surfactant is greater than 0.9:1. The combination of the cationionic:nonionic surfactant ratio with the alkoxylated methyl glucose ether thickener provides the composition with cold weather stability. Cold weather stability is observed when the composition remains transparent after cold storage.

Abstract: A composition for topical application in the auditory canal is provided. The composition includes 5% to 40% by weight on the total weight of the composition of an ester of vitamin E with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having from 1 to 19 carbon atoms, or an alkenyl or alkynyl radical having from 2 to 19 carbon atoms, and an oily vehicle selected from the group of hydrogenated polyisobutene, hydrogenated polydecene and mixtures of hydrogenated polyisobutene and/or hydrogenated polydecene with hydrogenated polyolefins, in particular hydrogenated C6-C14 hydrogenated polyolefins, Caprylic/Capric Triglyceride, Cyclopentasiloxane, and mixtures thereof. The composition can be used to remove earwax from the auditory canal as well as to normalize the epithelium of the auditory canal in cases of friction stress in individuals wearing hearing aids or in individuals using earplugs as hearing protection.

Abstract: The present application discloses hair conditioning compositions which provide effective hair conditioning, particularly to wavy or curly hair, the conditioning benefit lasting in the hair over several (up to 10) subsequent shampooings. The compositions comprise a film-forming polyester that is the reaction product of at least one diol, at least one polyol, and at least one dicarboxylic acid; polyquaternium-52 and/or polyquaternium-37; and at least one amino or aminopropyl-functional silicone, in an aqueous vehicle. The composition may additionally include dimethicone and/or a branched-chain ester. The method of conditioning hair using the defined compositions is also disclosed.

Abstract: The present invention features novel cosmetic skin care compositions for improving the appearance of skin, and particularly for improving the appearance of cellulite.

Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.

Abstract: The present invention relates to microgel particles containing nanotubes loaded with an active pharmaceutical ingredient, a process for their preparation and a pharmaceutical composition comprising the same.

Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.

Abstract: The present invention relates to a tablet having a weight of 30-200 mg and consisting of: 60-100 wt. % of granules consisting of: 50-90% by weight of the granules of dehydroepiandrosterone (DHEA); 6-35% by weight of the granules of microcrystalline cellulose; 0-20% by weight of the granules of one or more other pharmaceutically acceptable granule ingredients; and 0-40 wt. % of one or more other pharmaceutically acceptable tablet components. These tablets can suitably be used to orally administer DHEA in dosages of around 50 mg and are sufficiently small to be incorporated in, for instance, ordinary oral contraceptive blister packs.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.

Abstract: Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with the headache. Also provided herein are small smooth particulates comprising a 5HT1B/1D receptor agonist. Compositions for oral administration are described herein wherein the compositions comprise a combination of active agents, such as a 5HT1B/1D receptor agonist and one or more antiemetics.

Abstract: An aqueous composition comprising at least 10 weight percent of a dispersed esterified cellulose ether, based on the total weight of the aqueous composition, wherein the esterified cellulose ether comprises (i) groups of the formula —C(O)—R—COOH or (ii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOH, R being a divalent aliphatic or aromatic hydrocarbon group, and at least a part of the groups —C(O)—R—COOH are neutralized with an ammonium salt of carbonic acid, formic acid or acetic acid, and wherein d90 of the dispersed esterified cellulose ether particles is up to 10 micrometers, d90 being the diameter where 90 mass percent of the particles have a smaller equivalent diameter and the other 10 mass percent have a larger equivalent diameter, is useful for preparing coating dosage forms including tablets, capsules and others, or for the formation of capsules shells.

Abstract: Methods for inhibiting tissue ossification or calcification in a subject, comprising administering a therapeutically effective amount of BMP I inhibitor-loaded microparticles to a subject in need thereof, wherein the administration provides local and sustained release of the BMP I inhibitor thereby inhibiting tissue ossification or calcification.

Abstract: The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies.

Abstract: A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome; and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed.

Abstract: A method of making a facile, surface-independent, polyphenol coating is disclosed. In general, the method includes contacting at least a portion of the substrate to be coated with an aqueous solution containing one or more salts and one or more nitrogen-free phenolic compounds. Substrates of all kinds may be used, and compounds used to make the coating may include epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC) and epicatechin-3-gallate (ECG), tannic acid, gallic acid, pyrogallol, and/or other nitrogen-free phenolic compounds. The coating made using the method, methods of using the coating, and kits comprising the coating precursors are also disclosed.

Abstract: The present invention relates to the field of anti-malarials. In particular, the disclosure relates to methods for treating malaria in a subject by administering to said subject a potassium channel inhibitor. The disclosed potassium channel inhibitors provide wide bioavailability, long half-life, and good toxicity profiles while showing high potency for killing parasites which cause malaria. In certain exemplary embodiments, the potassium channel inhibitor is an inhibitor of calcium-activated potassium channels. In certain exemplary embodiments, the potassium channel inhibitor is an inhibitor of the Gardos channel.

Abstract: The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and/or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels, wherein the second compound is capable of entering nociceptors or pruriceptors through the channel-forming receptor when the receptor is activated. The invention also features a quarternary amine derivative or other permanently or transiently charged derivative of a compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels.

Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.

Abstract: Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).

Abstract: The present invention relates to a dosage regimen of ST10 (ferric trimaltol) for the treatment of patients suffering from iron deficiency with or without anaemia. Specifically the invention relates to the treatment of patients with 30 mg ST10 twice daily.

Abstract: The invention discloses statins compounds used as local intraosseous application for the treatment of ischemic diseases, in particular, discloses local intraosseous application of statin compounds in the treatment of peripheral ischemic diseases or cardio-cerebrovascular ischemic diseases.

Abstract: The present invention relates to melatonin or a pharmaceutically acceptable salt thereof for use as a medicament, the use of melatonin or a pharmaceutically acceptable salt thereof for the preparation of medicament, the use of melatonin as a food supplement and a pharmaceutical unit dosage form.

Abstract: The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: The disclosure relates to substituted pyridines, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.

Abstract: Described herein are dosing regimens and kits for the treatment and/or prevention of lysosomal storage disorders such as Gaucher disease. Also described are dosing regimens and kits for the treatment and/or prevention of degenerative disorders of the central nervous system, such as the synucleinopathies Parkinson's disease or Lewy Body Dementia.

Abstract: A method of treating or preventing capsular contracture in a patient resulting from surgical insertion of a silicone breast implant in a surgically created implant pocket. The method includes administering to the patient a therapeutically effective amount of a leukotriene receptor antagonist prior to the formation of a capsular contracture in the patient. The method further includes administering a therapeutically effective amount of displacement of the breast implant within the surgically created implant pocket, the therapeutically effective amount of displacement of the breast implant being administered post-surgically but prior to the formation of a capsular contracture in the patient.

Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.